Vasella helps Numab to CHF22M round ahead of cancer trial start

Vasella helps Numab to CHF22M round ahead of cancer trial start

Source: 
Fierce Biotech
snippet: 

Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.